INCIDENCE OF SUSTAINED OCULAR HYPERTENSION USING PREPACKAGED VERSUS FRESHLY PREPARED INTRAVITREAL BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
| Autor: | Storey PP; Mid Atlantic Retina, The Retina Service of Wills Eye Hospital, Philadelphia, Pennsylvania; †Emory Eye Center, Emory University, Atlanta, Georgia; ‡Division of Biostatistics, Jefferson Medical College, Philadelphia, Pennsylvania; and §USC Eye Institute, University of Southern California, Los Angeles, California., Ho V, Yeh S, Reddy S, Fang-Yen NH, Pequignot E, Leiby BE, Fineman M, Garg S, Hubbard GB 3rd, Hsu J |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | Retina (Philadelphia, Pa.) [Retina] 2015 Oct; Vol. 35 (10), pp. 1992-2000. |
| DOI: | 10.1097/IAE.0000000000000620 |
| Abstrakt: | Purpose: To compare the incidence of sustained ocular hypertension (OHT) after intravitreal injections of prepackaged versus freshly prepared bevacizumab monotherapy for the treatment of neovascular age-related macular degeneration. Methods: Charts of 1,216 patients with neovascular age-related macular degeneration receiving intravitreal bevacizumab monotherapy at 2 retina practices using different preparations of bevacizumab between January 1, 2009, and December 31, 2011, were reviewed. Primary outcome was incidence of sustained OHT, defined as intraocular pressure > 25 mmHg with an increase ≥ 6 from baseline on ≥ 2 consecutive visits or requiring treatment. Results: A total of 6,479 injections in 740 eyes of 634 patients were included and 14 eyes (0.81% incidence per eye-year) developed sustained OHT. For eyes receiving prepackaged bevacizumab, 10 of 339 eyes (1.39% incidence per eye-year) developed sustained OHT compared with 4 of 401 eyes (0.39% incidence per eye-year) receiving freshly prepared bevacizumab, giving an incidence rate ratio of 3.55 (95% confidence interval, 0.93-13.49; P = 0.063). All eyes that developed sustained OHT achieved intraocular pressure control with observation or topical therapy alone. Conclusion: Incidence of sustained OHT after intravitreal bevacizumab is low. We found a trend toward higher rates of sustained OHT with prepackaged bevacizumab although this difference was not statistically or clinically significant. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|